Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17603684 | 0.82 | KDM1A (0.47) | KDM1AMAOBSIGMAR1TSHRALDH1A1 | |
| SCHEMBL27889440 | 0.81 | KDM1A (0.46) | KDM1AMAOBSIGMAR1TSHRALDH1A1 | |
| SCHEMBL17603661 | 0.79 | KDM1A (0.44) | KDM1AMAOBSIGMAR1TSHRALDH1A1 | |
| SCHEMBL4737865 | 0.79 | HDAC9 (0.44) | KDM1AMAOBSIGMAR1TSHRHDAC9 | |
| SCHEMBL4735703 | 0.79 | HDAC9 (0.44) | KDM1AMAOBSIGMAR1TSHRHDAC9 | |
| SCHEMBL7330436 | 0.78 | SIGMAR1 (0.44) | KDM1AMAOBSIGMAR1MEN1KMT2A | |
| SCHEMBL7154324 | 0.78 | MAOB (0.50) | KDM1AMAOBSIGMAR1TSHRALDH1A1 | |
| SCHEMBL9280563 | 0.78 | SIGMAR1 (0.44) | KDM1AMAOBSIGMAR1MEN1KMT2A | |
| SCHEMBL4736099 | 0.77 | KDM1A (0.42) | KDM1AMAOBSIGMAR1TSHRALDH1A1 | |
| SCHEMBL29453777 | 0.77 | KDM1A (0.42) | KDM1AMAOBSIGMAR1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266532-B2 | Tricyclic modulators of TNF signaling | ABBVIE INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-10266532-B2 | Tricyclic modulators of TNF signaling | ABBVIE INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-06-28 | — | — | US | disclosed |
| EP-3288939-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | AbbVie Inc. (US) | 2018-03-07 | — | — | EP | disclosed |
| US-9856253-B2 | Tricyclic modulators of TNF signaling | ABBVIE, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-9856253-B2 | Tricyclic modulators of TNF signaling | ABBVIE, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| WO-2016168641-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| EP-1979348-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-01-18 | — | — | EP | disclosed |
| US-20110281854-A1 | MORPHOLINE COMPOUNDS | PFIZER INC | 2011-11-17 | — | — | US | disclosed |
| US-20110160233-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| US-7910595-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2011-03-22 | — | — | US | disclosed |
| US-20090192145-A1 | Spiro-Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192145-A1 | Spiro-Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
| CN-101384591-A | Antiviral compounds | ABBOTT LAB (US) | 2009-03-11 | — | — | CN | disclosed |
| EP-1979348-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007076034-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160233-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | KDM1A 2649/4885MAOB 3352/4885SIGMAR1 1364/4885 |
| US-20110281854-A1 | MORPHOLINE COMPOUNDS | REN, MC2R, NR3C2 | KDM1A 3924/4885MAOB 1374/4885SIGMAR1 1097/4885 |
| US-20090192145-A1 | Spiro-Imidazo Compounds | REN, NR3C2, AGTR1 | KDM1A 3697/4885MAOB 902/4885SIGMAR1 611/4885 |
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | KDM1A 2649/4885MAOB 3352/4885SIGMAR1 1364/4885 |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | TNF, TNFRSF1A, CD40 | KDM1A 4732/4885MAOB 2977/4885SIGMAR1 1077/4885 |
| US-10266532-B2 | Tricyclic modulators of TNF signaling | TNF, TNFRSF1A, CD40 | KDM1A 4732/4885MAOB 2977/4885SIGMAR1 1077/4885 |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | TNF, TNFRSF1A, CD40 | KDM1A 4732/4885MAOB 2977/4885SIGMAR1 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.